dc.creator | Siskou O., Korompoki E., Ntaios G., Tsampalas E., Alexopoulou H., Kalliontzakis I., Kouridaki A., Tountopoulou A., Kouzi I., Vasilopoulou S., Milionis H., Evaggelou H., Karagkiozi E., Hatzitolios A.I., Savopoulos C., Myrou A., Manios E., Mavraganis G., Vemmou A., Kaitelidou D., Galanis P., Papastefanatos S., Konstantakopoulou O., Karagkouni I., Vemmos K. | en |
dc.date.accessioned | 2023-01-31T09:57:12Z | |
dc.date.available | 2023-01-31T09:57:12Z | |
dc.date.issued | 2020 | |
dc.identifier | 10.3233/SHTI200585 | |
dc.identifier.isbn | 9781643680927 | |
dc.identifier.issn | 09269630 | |
dc.identifier.uri | http://hdl.handle.net/11615/79057 | |
dc.description.abstract | The aim of this study was to evaluate accessibility of stroke patients to optimal healthcare technology in Greece. Methods: The study population consisted of 313 first ever stroke patients derived from the 'Stroke Units Necessity for Patients, SUN4P' registry. Descriptive statistics were used, to present patients' characteristics and resources utilization Results: The vast majority of patients (91.7%) conducted a CT scan during the acute phase (within the first 24hours). Almost, (65%) were admitted to wards of Internal Medicine Departments, whereas only 21% of patients were admitted to a Stroke Unit. Of note, a total of 6.9% of ischemic stroke patients received intravenous thrombolytic therapy with recombinant tissue plasminogen activator (rtPA). Conclusions: Preliminary results from SUN4P underline the urgent necessity for the re-organization of acute stroke care in Greece, as rates of admissions to stroke units and rtPA treatment during the acute phase are currently below optimal. © 2020 The authors and IOS Press. | en |
dc.language.iso | en | en |
dc.source | Studies in Health Technology and Informatics | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85087432766&doi=10.3233%2fSHTI200585&partnerID=40&md5=b724f6e52624e0bcb824a51cb43e500c | |
dc.subject | Computerized tomography | en |
dc.subject | Drug therapy | en |
dc.subject | Medicine | en |
dc.subject | Descriptive statistics | en |
dc.subject | Healthcare technology | en |
dc.subject | Internal medicine | en |
dc.subject | Ischemic strokes | en |
dc.subject | Recombinant tissue plasminogen activators | en |
dc.subject | Resources utilizations | en |
dc.subject | Stroke patients | en |
dc.subject | Thrombolytic therapies | en |
dc.subject | Medical informatics | en |
dc.subject | fibrinolytic agent | en |
dc.subject | tissue plasminogen activator | en |
dc.subject | administrative personnel | en |
dc.subject | brain ischemia | en |
dc.subject | cerebrovascular accident | en |
dc.subject | fibrinolytic therapy | en |
dc.subject | Greece | en |
dc.subject | human | en |
dc.subject | treatment outcome | en |
dc.subject | Administrative Personnel | en |
dc.subject | Brain Ischemia | en |
dc.subject | Fibrinolytic Agents | en |
dc.subject | Greece | en |
dc.subject | Humans | en |
dc.subject | Stroke | en |
dc.subject | Thrombolytic Therapy | en |
dc.subject | Tissue Plasminogen Activator | en |
dc.subject | Treatment Outcome | en |
dc.subject | IOS Press | en |
dc.title | Access of stroke patients' to optimal healthcare technology in Greece: Messages to policy makers | en |
dc.type | conferenceItem | en |